PLYMOUTH
MEETING, Pa., April 28,
2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a
biotechnology company focused on developing and commercializing DNA
medicines to help treat and protect people from HPV-associated
diseases, cancer, and infectious diseases, today announced that
first quarter 2023 financial results will be released after the
market close on May 10, 2023.
Following the release, INOVIO will host a live conference call and
webcast at 4:30 p.m. ET to discuss
financial results and provide a general business update.
A live and archived version of the audio presentation will be
available online at
http://ir.inovio.com/events-and-presentations/default.aspx. This is
a listen-only event but will include a live Q&A with
analysts.
About INOVIO
INOVIO is a biotechnology company focused on developing and
commercializing DNA medicines to help treat and protect people from
HPV-associated diseases, cancer, and infectious diseases. INOVIO's
DNA medicines in development are delivered using its
investigational proprietary smart device, CELLECTRA®, to
produce immune responses against targeted pathogens and cancers.
For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson (267)
429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267)
440-4298 thomas.hong@inovio.com
View original
content:https://www.prnewswire.com/news-releases/inovio-to-report-first-quarter-2023-financial-results-on-may-10-2023-301810322.html
SOURCE INOVIO Pharmaceuticals, Inc.